论文部分内容阅读
目的本文目的是分析右室梗塞患者的临床特点及卡托普利治疗的作用。方法用多中心随机安慰剂对照临床试验方法，重点分析中国心脏研究—Ｉ中右室梗塞患者住院４周病死率和并发症及卡托普利的影响。结果试验四周内，右室梗塞者总病死率（１６．７％）、心力衰竭（２９．０％）、心源性休克（１２．０％）、室颤（６．７％）、其它类型心跳骤停（４．４％）、Ｉ／ＩＩ度房室传导阻滞（１４．６％）、脑卒中（２．２％）、低血压（１６．７％）发生率均高于非右室梗塞者（９．４％、１７．６％、４．４％、３．１％、２．３％、４．８％、１．２％、１３．４％）。卡托普利治疗４周，轻微增加了病死率，轻微增加心源性休克发生率。结论右室梗塞患者系高危病人，卡托普利早期治疗无益
The purpose of this paper is to analyze the clinical features of patients with right ventricular infarction and the role of captopril. Methods A multicenter randomized placebo-controlled clinical trial focused on the 4-week hospital-based mortality and complications of captopril in Chinese Heart Study-I and the effects of captopril. Results In the four weeks after the trial, the total case fatality rate (16.7%) in patients with right ventricular infarction, heart failure (29.0%), cardiogenic shock (12.0%), ventricular fibrillation Cardiac arrest (4.4%), I / II degree atrioventricular block (14.6%), stroke (2.2%), hypotension (16.7%) were higher than non-right Ventricular infarction (9.4%, 17.6%, 4.4%, 3.1%, 2.3%, 4.8%, 1.2%, 13.4%). Captopril treatment for 4 weeks slightly increased mortality and slightly increased the incidence of cardiogenic shock. Conclusion Patients with right ventricular infarction are high-risk patients, and captopril early treatment is not helpful